| meta-analysis | Q815382 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1022451369 |
| P356 | DOI | 10.1007/S13277-014-1693-7 |
| P698 | PubMed publication ID | 24557541 |
| P2093 | author name string | Qin Wang | |
| Yajie Wang | |||
| Jianchun Gu | |||
| Xiaoping Li | |||
| Leizhen Zheng | |||
| Meiling Zhu | |||
| P2860 | cites work | Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 |
| Measuring inconsistency in meta-analyses | Q27860655 | ||
| Practical methods for incorporating summary time-to-event data into meta-analysis | Q28131754 | ||
| HER2 as a Prognostic Marker in Gastric Cancer - A Systematic Analysis of Data from the Literature | Q34223664 | ||
| Clinicopathological characteristics and prognostic analysis of Lauren classification in gastric adenocarcinoma in China. | Q34623247 | ||
| Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review | Q34631121 | ||
| HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer | Q34638138 | ||
| Association between HSP90 and Her2 in gastric and gastroesophageal carcinomas | Q34852929 | ||
| HER-2 Evaluation in a Specific Gastric Cancer Population with the Highest Rate of Mortality in Spain | Q35495307 | ||
| Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients | Q35642359 | ||
| Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial | Q36630742 | ||
| Assessment of a HER2 scoring system for gastric cancer: results from a validation study | Q37142266 | ||
| HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target | Q37149210 | ||
| HER2 testing in gastric cancer | Q37822236 | ||
| HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications. | Q38014506 | ||
| Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population | Q38083585 | ||
| Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis | Q38122908 | ||
| The incidence and prognostic value of HER2 overexpression and cyclin D1 expression in patients with gastric or gastroesophageal junction adenocarcinoma in Israel | Q41996754 | ||
| HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing | Q42431264 | ||
| Gastric Cancer Working Group Report | Q42876512 | ||
| Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial | Q43712233 | ||
| Lymphatic vascular invasion is an independent correlated factor for lymph node metastasis and the prognosis of resectable T2 gastric cancer patients | Q44234766 | ||
| Effect of HER-2/neu over-expression on prognosis in gastric cancer: a meta-analysis | Q44827901 | ||
| Prognostic value of tumor size in gastric cancer: an analysis of 2,379 patients | Q47260613 | ||
| Significance of TFF3 protein and Her-2/neu status in patients with gastric adenocarcinoma. | Q50861266 | ||
| HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. | Q50889414 | ||
| Clinicopathological characteristics and prognostic analysis of gastric cancer in the young adult in China. | Q51526385 | ||
| Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. | Q51823758 | ||
| HER2 expression in gastric cancer: Rare, heterogeneous and of no prognostic value - conclusions from 924 cases of two independent series. | Q52848050 | ||
| Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. | Q53128686 | ||
| Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. | Q54483761 | ||
| Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment. | Q54497269 | ||
| Prognostic analysis in node-negative gastric cancer patients in China | Q83012629 | ||
| The effectiveness of the new (7th) UICC N classification in the prognosis evaluation of gastric cancer patients: a comparative study between the 5th/6th and 7th UICC N classification | Q83498873 | ||
| HER2 expression and its clinicopathological features in resectable gastric cancer | Q83629811 | ||
| P433 | issue | 6 | |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 5315-5321 | |
| P577 | publication date | 2014-02-21 | |
| P1433 | published in | Tumor Biology | Q15757842 |
| P1476 | title | Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis | |
| P478 | volume | 35 |
| Q26774528 | Advanced gastric cancer: What we know and what we still have to learn |
| Q90609239 | Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy |
| Q40212670 | Association of HER2 codon 655 polymorphism with ovarian cancer |
| Q37012387 | Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection: A large-scale multicenter study in China |
| Q52880999 | Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study. |
| Q54365119 | Comment on Gu et al. entitled "Prognostic significance of HER2 expression based on trastuzumab for gastric cancer (ToGA) criteria in gastric cancer: an updated meta-analysis". |
| Q47190729 | Correlation of Trastuzumab-based Treatment with Clinical Characteristics and Prognosis in HER2-Positive Gastric and gastroesophageal Junction Cancer: A retrospective single center analysis. |
| Q51180085 | Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma. |
| Q28078111 | HER2 aberrations and heterogeneity in cancers of the digestive system: Implications for pathologists and gastroenterologists |
| Q35029025 | HER2 expression in gastric and oesophageal cancer: a meta-analytic review |
| Q37523508 | Her2/neu Protein Expression and Oncogene Amplification in Gastric Carcinoma with Clinico-Pathological Correlation in Egyptian Patients. |
| Q37392861 | JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients |
| Q55359616 | Optimal management of resected gastric cancer. |
| Q26774521 | Personalized medicine in gastric cancer: Where are we and where are we going? |
| Q39453559 | Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment |
| Q54316753 | Prognosis significance of HER2 status and TACC1 expression in patients with gastric carcinoma. |
| Q92073923 | Prognostic Biomarkers for Gastric Cancer: An Umbrella Review of the Evidence |
| Q36194219 | S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial |
| Q53667030 | TFF3 and HER2 expression and their correlation with survival in gastric cancer. |
| Q38364292 | Targeted therapy in gastric cancer |
Search more.